Scholarlink

<p>Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes (DM2), associated with increasing disability and mortality despite therapeutic advances. Studies on GLP-1 receptor agonists (GLP-1RA) and tirzepatide, a dual GIP/GLP-1 agonist, have shown promising nephroprotective effects. This review summarises the evidence on the renal benefits of GLP-1RA and tirzepatide, exploring potential underlying mechanisms. Further studies are needed to confirm their impact on renal outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effetti renali dei farmaci basati sul sistema delle incretine nelle persone con diabete di tipo 2

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月27日

查看全文
  • Irene Caruso,
  • Carlotta Amato,
  • Francesco Gravina,
  • Annalisa Montingelli,
  • Francesco Giorgino,
  • Luigi Laviola

摘要

Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes (DM2), associated with increasing disability and mortality despite therapeutic advances. Studies on GLP-1 receptor agonists (GLP-1RA) and tirzepatide, a dual GIP/GLP-1 agonist, have shown promising nephroprotective effects. This review summarises the evidence on the renal benefits of GLP-1RA and tirzepatide, exploring potential underlying mechanisms. Further studies are needed to confirm their impact on renal outcomes.